Thus, an in-depth exploration of the multiple regulatory mechanisms associated with Apelin-13 and the development of related clinical therapeutic drugs will provide more new ideas and individualized targets for the prevention and treatment of metabolic diseases. This evidence concerns the gene APLN and metabolic disease.